<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02523092</url>
  </required_header>
  <id_info>
    <org_study_id>15-17300</org_study_id>
    <nct_id>NCT02523092</nct_id>
  </id_info>
  <brief_title>Use of CXCL9 as a Biomarker of Acthar Efficacy</brief_title>
  <acronym>Acthar</acronym>
  <official_title>Use of CXCL9 as a Biomarker of Acthar Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is this study is to test whether use of Acthar gel in the context of
      sarcoidosis will lead to improved symptoms and lung function and correlate with decreased
      levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will test whether Acthar gel's anti-inflammatory properties will modulate
      immune cells and lead to decreases in blood biomarkers and improvements in clinical
      parameters. Specific Aim 1 will examine the levels of the predictive biomarker, chemokine
      ligand 9 (CXCL9), and related transcripts, and determine whether they decrease in
      participants over time while taking Acthar. Specific Aim 2 will test whether the biologic
      changes measured in blood correlate to clinical markers, including lung function and symptom
      scores. Since the investigators have found that CXCL9 predicts clinical course, they
      hypothesize that CXCL9 transcript levels in the blood will decrease over time in pulmonary
      sarcoidosis participants whose clinical outcome measures improve with Acthar.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in blood CXCL9 levels by 50%</measure>
    <time_frame>within 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in FVC by 5% of predicted</measure>
    <time_frame>within 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in dyspnea score</measure>
    <time_frame>within 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Acthar gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 4-week period of baseline monitoring, Acthar gel will be administered by intramuscular or subcutaneous injection. Initial dosing will be 40 U every 72 hours (or twice per week) for 4 weeks. Dosage will then be increased to 80 U with similar frequency for 8 weeks and up to 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar gel</intervention_name>
    <description>Acthar gel given IM or SQ as per package insert</description>
    <arm_group_label>Acthar gel</arm_group_label>
    <other_name>Acthar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven diagnosis of sarcoidosis with demonstrated pulmonary involvement

          -  Refractoriness to or intolerance of immunosuppressive agents like prednisone or
             methotrexate

        Exclusion Criteria:

          -  Smoking

          -  Cancer

          -  Chronic infections (e.g. tuberculosis, viral, fungal, bacterial)

          -  Inflammatory conditions

          -  Coexisting lung disease

          -  Congestive heart failure

          -  Uncontrolled hypertension

          -  Recent surgery

          -  Active peptic ulcers

          -  Osteoporosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Koth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zoe Lehman, BA</last_name>
    <phone>415-476-9637</phone>
    <email>zoe.lehman@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Koth, MD</last_name>
    <phone>415-514-4369</phone>
    <email>laura.koth@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Koth, MD</last_name>
      <phone>415-514-4369</phone>
      <email>laura.koth@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Koth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://sarcoidosis.ucsf.edu/</url>
    <description>Homepage for the Sarcoidosis Research Program at the University of California, San Francisco</description>
  </link>
  <reference>
    <citation>Su R, Li MM, Bhakta NR, Solberg OD, Darnell EP, Ramstein J, Garudadri S, Ho M, Woodruff PG, Koth LL. Longitudinal analysis of sarcoidosis blood transcriptomic signatures and disease outcomes. Eur Respir J. 2014 Oct;44(4):985-93. doi: 10.1183/09031936.00039714. Epub 2014 Aug 19.</citation>
    <PMID>25142485</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2015</study_first_submitted>
  <study_first_submitted_qc>August 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>October 3, 2016</last_update_submitted>
  <last_update_submitted_qc>October 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Laura L. Koth, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>sarcoidosis</keyword>
  <keyword>Acthar</keyword>
  <keyword>CXCL9</keyword>
  <keyword>chemokine ligand 9</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

